X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20959) 20959
Newsletter (184) 184
Newspaper Article (170) 170
Book Chapter (52) 52
Dissertation (9) 9
Conference Proceeding (3) 3
Government Document (3) 3
Book Review (2) 2
Book / eBook (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12178) 12178
animals (11866) 11866
fibroblasts (6613) 6613
mice (6028) 6028
cells, cultured (4995) 4995
cell biology (4630) 4630
expression (4215) 4215
male (3905) 3905
fibroblasts - metabolism (3778) 3778
signal transduction (3539) 3539
female (3350) 3350
biochemistry & molecular biology (3224) 3224
rats (3102) 3102
gene expression (2864) 2864
proteins (2858) 2858
fibroblasts - drug effects (2742) 2742
oncology (2664) 2664
cancer (2295) 2295
apoptosis (2272) 2272
research (2268) 2268
phosphorylation (2186) 2186
cell line (2158) 2158
activation (2141) 2141
growth factors (2004) 2004
research article (1991) 1991
inflammation (1980) 1980
cells (1963) 1963
fibrosis (1890) 1890
kinases (1857) 1857
fibroblast growth factors (1845) 1845
angiogenesis (1798) 1798
fibroblasts - cytology (1784) 1784
multidisciplinary sciences (1751) 1751
medicine (1721) 1721
analysis (1671) 1671
gene-expression (1667) 1667
cell proliferation (1658) 1658
cytokines (1621) 1621
signal transduction - drug effects (1604) 1604
stem cells (1586) 1586
collagen (1548) 1548
physiological aspects (1529) 1529
proliferation (1516) 1516
differentiation (1501) 1501
rodents (1481) 1481
cell line, tumor (1454) 1454
physiology (1439) 1439
cell proliferation - drug effects (1381) 1381
biology (1376) 1376
science (1350) 1350
in-vitro (1345) 1345
fibroblast-growth-factor (1311) 1311
inhibition (1293) 1293
enzyme inhibitors - pharmacology (1283) 1283
growth (1254) 1254
medicine, research & experimental (1253) 1253
mice, inbred c57bl (1224) 1224
adult (1211) 1211
tumors (1177) 1177
health aspects (1161) 1161
immunology (1157) 1157
fibroblasts - pathology (1144) 1144
neurosciences (1138) 1138
pharmacology & pharmacy (1137) 1137
middle aged (1117) 1117
rna, messenger - metabolism (1101) 1101
disease models, animal (1097) 1097
dose-response relationship, drug (1095) 1095
developmental biology (1076) 1076
growth-factor (1064) 1064
cell differentiation (1056) 1056
genetic aspects (1034) 1034
immunohistochemistry (1030) 1030
rats, sprague-dawley (1024) 1024
blotting, western (1013) 1013
fibroblast growth factor 2 - pharmacology (1005) 1005
receptor (1001) 1001
care and treatment (995) 995
extracellular matrix (985) 985
fibroblast growth factor (967) 967
time factors (930) 930
mutation (920) 920
cell division - drug effects (918) 918
in-vivo (916) 916
tgf-beta (909) 909
signal transduction - physiology (899) 899
metastasis (896) 896
biochemistry (870) 870
reverse transcriptase polymerase chain reaction (869) 869
mice, knockout (860) 860
gene expression regulation (838) 838
transfection (830) 830
up-regulation (826) 826
cell growth (822) 822
receptors (814) 814
vascular endothelial growth factor (804) 804
growth-factor-beta (801) 801
fibroblast growth factors - metabolism (797) 797
pathogenesis (793) 793
cell cycle (788) 788
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21321) 21321
Japanese (108) 108
Chinese (42) 42
French (17) 17
German (17) 17
Russian (8) 8
Portuguese (6) 6
Hungarian (4) 4
Norwegian (3) 3
Dutch (2) 2
Italian (2) 2
Spanish (2) 2
Danish (1) 1
Korean (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology, ISSN 0923-7534, 2014, Volume 25, Issue 3, pp. 552 - 563
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2014, Volume 111, Issue 45, pp. E4869 - E4877
The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation.... 
Structure-based drug design | Drug discovery | Cancer drug resistance | Kinase inhibitor | structure-based drug design | WILD-TYPE | MULTIDISCIPLINARY SCIENCES | BCR-ABL | GROWTH-FACTOR RECEPTORS | DRUG-RESISTANCE | kinase inhibitor | LUNG-CANCER | GENE FUSIONS | cancer drug resistance | SELECTIVE INHIBITOR | drug discovery | THERAPEUTIC TARGET | FACTOR RECEPTOR 4 | REGULATES PROLIFERATION | Receptor, Fibroblast Growth Factor, Type 4 - chemistry | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Receptor, Fibroblast Growth Factor, Type 2 - chemistry | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | ErbB Receptors - genetics | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Crystallography, X-Ray | Structure-Activity Relationship | Mutation, Missense | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Protein Kinase Inhibitors - chemistry | Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Binding Sites | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Neoplasms - enzymology | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | ErbB Receptors - chemistry | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - chemistry | Neoplasms - pathology | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Amino Acid Substitution | Drug Resistance, Neoplasm - drug effects | Biological Sciences | PNAS Plus
Journal Article
Oncogene, ISSN 1476-5594, 2012, Volume 32, Issue 25, pp. 3059 - 3070
Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers, making them attractive drug targets... 
tyrosine kinase inhibitors | ERK1/2 | FGFR | PKB | acquired resistance | MULTIPLE-MYELOMA | BLADDER-CANCER | PHOSPHORYLATION | PROTEIN-KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | STOMACH-CANCER | LINES | CELL BIOLOGY | C/EBP-ALPHA | AMPLIFICATION | GENE | ONCOLOGY | GASTRIC-CANCER | GENETICS & HEREDITY | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Multiple Myeloma - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Pyrazoles - pharmacology | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Pyrimidines - pharmacology | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Receptor Protein-Tyrosine Kinases - drug effects | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Signal Transduction - drug effects | Receptors, Fibroblast Growth Factor - metabolism | Cell Line, Tumor | Mutation | Multiple Myeloma - genetics | Gene mutations | Analysis | Physiological aspects | Genetic aspects | Fibroblast growth factors | Research | Health aspects | Fibroblast growth factor receptors | Proteins | Signal transduction | Inhibitor drugs | Gene expression | Cancer
Journal Article
PLoS medicine, ISSN 1549-1676, 2008, Volume 5, Issue 1, pp. e19 - 0138
Background Important support functions, including promotion of tumor growth, angiogenesis, and invasion, have been attributed to the different cell types populating the tumor stroma, i.e... 
HUMAN BREAST-CARCINOMA | MEDICINE, GENERAL & INTERNAL | TGF-BETA | GROWTH-FACTOR-RECEPTOR | SQUAMOUS CARCINOGENESIS | TYPE-16 TRANSGENIC MICE | FACTOR-BETA-RECEPTOR | CELL INVASION | MOUSE MODEL | TISSUE STROMA | CERVICAL-CANCER | Fibroblast Growth Factor 7 - physiology | Fibroblasts - enzymology | Uterine Cervical Neoplasms - blood supply | Humans | Carcinoma - virology | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Receptors, Platelet-Derived Growth Factor - physiology | Proto-Oncogene Proteins c-kit - biosynthesis | Neovascularization, Pathologic - physiopathology | Neoplasm Proteins - genetics | Carcinoma - drug therapy | Estradiol - administration & dosage | Receptors, Platelet-Derived Growth Factor - genetics | Mice, Transgenic | Piperazines - therapeutic use | Uterine Cervical Neoplasms - physiopathology | Pyrimidines - pharmacology | Fibroblast Growth Factor 7 - biosynthesis | Piperazines - pharmacology | Carcinoma - physiopathology | Stromal Cells - secretion | Fibroblast Growth Factor 2 - genetics | Neovascularization, Pathologic - drug therapy | Fibroblasts - drug effects | Carcinoma - blood supply | Mice | Fibroblasts - secretion | Epithelial Cells - metabolism | Neoplasm Proteins - physiology | Platelet-Derived Growth Factor - genetics | Human papillomavirus 16 | Paracrine Communication - physiology | Stromal Cells - enzymology | Stromal Cells - drug effects | Female | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Fibroblast Growth Factor 2 - physiology | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Neoplasm Proteins - biosynthesis | Pericytes - metabolism | Fibroblast Growth Factor 2 - biosynthesis | Uterine Cervical Neoplasms - drug therapy | Mice, Inbred Strains | Imatinib Mesylate | Fibroblast Growth Factor 7 - genetics | Animals | Estradiol - toxicity | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Paracrine Communication - drug effects | Uterine Cervical Neoplasms - virology | Protein Kinase Inhibitors - pharmacology | Benzamides | Platelet-Derived Growth Factor - physiology | Platelet-Derived Growth Factor - antagonists & inhibitors | Proteins | Medical research | Human papillomavirus | Cervical cancer | Tumors | Index Medicus | Oncology | Gynecological | Chemotherapy | Cancer
Journal Article
Cell metabolism, ISSN 1550-4131, 2013, Volume 17, Issue 2, pp. 225 - 235
.... Rederivation of Fxr-deficient mice as GF demonstrated that the gut microbiota regulated expression of fibroblast growth factor 15 in the ileum and cholesterol 7α-hydroxylase (CYP7A1... 
ACTIVATION | DISRUPTION | STEROIDS | LIVER | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | FARNESOID-X-RECEPTOR | GERM-FREE | ABSORPTION | DIFFERENTIAL REGULATION | BINDING | CELL BIOLOGY | Organ Specificity - drug effects | Taurocholic Acid - metabolism | Fibroblast Growth Factors - genetics | Ileum - metabolism | Gene Expression Profiling | Fibroblast Growth Factors - metabolism | Organ Specificity - genetics | Ileum - drug effects | Metagenome - genetics | Absorption | Liver - drug effects | Taurocholic Acid - analogs & derivatives | Taurocholic Acid - pharmacology | Metagenome - drug effects | Liver - metabolism | Gastrointestinal Tract - microbiology | Bile Acids and Salts - metabolism | Gastrointestinal Tract - drug effects | Gene Expression Regulation - drug effects | Cholesterol 7-alpha-Hydroxylase - genetics | Animals | Cholesterol 7-alpha-Hydroxylase - metabolism | Models, Biological | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Feedback, Physiological - drug effects | Anti-Bacterial Agents - pharmacology | Mice | Receptors, Cytoplasmic and Nuclear - metabolism | Physiological aspects | Fibroblast growth factors | Universities and colleges | Cytochrome P-450 | Deoxycholic acid | Cell and Molecular Biology | Clinical Medicine | Klinisk medicin | Cell- och molekylärbiologi | Gastroenterology and Hepatology | Gastroenterologi
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 4, pp. 338 - 348
Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR alterations... 
MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | MULTICENTER | THERAPY | COMPREHENSIVE MOLECULAR CHARACTERIZATION | JNJ-42756493 | CHEMOTHERAPY | Quinoxalines - adverse effects | Quinoxalines - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Treatment Outcome | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Urologic Neoplasms - pathology | Pyrazoles - administration & dosage | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Progression-Free Survival | Receptors, Fibroblast Growth Factor - genetics | Aged, 80 and over | Adult | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - adverse effects | Urothelium | Cancer patients | Diagnosis | Bladder cancer | Health aspects | Tyrosine | Creatinine | Fibroblast growth factor | Research & development--R&D | Immune clearance | Metastasis | Gene expression | Kinases | Survival | Metastases | Chemotherapy | Immunotherapy | Response rates | Antitumor activity | Editorials | Urothelial carcinoma | Fibroblast growth factor receptor 1 | Protein-tyrosine kinase | Drug dosages | Fibroblast growth factor receptors | Receptors, Fibroblast Growth Factor / genetics | Life Sciences | Urologic Neoplasms / drug therapy | Protein Kinase Inhibitors / administration & dosage | Antineoplastic Agents / administration & dosage | Quinoxalines / administration & dosage | Receptors, Fibroblast Growth Factor / antagonists & inhibitors | Pharmaceutical sciences | Pyrazoles / administration & dosage | Cancer
Journal Article